Multicentre 2×2 Factorial Randomised Study Comparing Tirofiban Versus Abciximab and SES Versus BMS in AMI

Overview

The purpose of this study is to determine which from the four combinations tirofiban+sirolimus eluting stent (SES), tirofiban+bare metal stent (BMS), abciximab+SES, abciximab+BMS is the possible gold standard treatment for ST-segment elevation myocardial infarction in terms of efficacy and cost-efficacy.

Full Title of Study: “Multicentre 2×2 Factorial Randomised Study Comparing Tirofiban Administered With the Single High-Dose Bolus Versus Abciximab and Sirolimus Eluting Stent Versus Bare Metal Stent in Acute Myocardial Infarction – MULTI-STRATEGY Trial”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Factorial Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: April 2007

Detailed Description

The combination abciximab plus bare metal stent (BMS) is currently considered the standard therapy for AMI. The use of sirolimus eluting stent (SES) is related to a reduction of the need for urgent target vessel revascularization (TVR). With current acquisition prices for abciximab and SES, replacing abciximab with tirofiban, administered as a single high-dose bolus (SHDB) regimen, is a promising strategy that would preserve financial resources. In a recent study the combination tirofiban and SES resulted to be associated to an overall lower major adverse cardiovascular events (MACE) rate with respect to the abciximab plus BMS. However, since no conclusion can be drawn yet regarding the relative contribution of a specific GP IIb/IIIa inhibitor or a stent type with respect to the other, the combination of abciximab and SES may be associated to an even lower event rate with respect to SHDB tirofiban and SES, thus offsetting the higher initial cost. Comparison(s): four strategies (SHDB tirofiban + BMS, SHDB tirofiban + SES, abciximab + BMS, abciximab + SES) are compared to determine the possible gold standard treatment for ST-segment elevation myocardial infarction in terms of efficacy and cost-efficacy.

Interventions

  • Other: abciximab followed by implantation of bare metal stent
    • Patients will receive infusion of abciximab at standard regimen before undergoing intervention for STEMI and then bare metal stent implantation in the culprit lesion
  • Other: abciximab and Sirolimus eluting stent
    • Patients will receive abciximab infusion at standard regimen followed by implantation of sirolimus-eluting stent in the culprit lesion
  • Other: tirofiban and bare metal stent
    • Patients will receive tirofiban infusion at high loading dose followed by standard infusion for 18-24 hours and subsequently they will be treated with bare metal stent implantation
  • Other: tirofiban and sirolimus-eluting stent
    • Patients will receive tirofiban infusion at high loading dose followed by standard infusion for 18-24 hours and subsequently they will be treated with sirolimus-eluting stent implantation

Arms, Groups and Cohorts

  • Active Comparator: 1
    • Patients will receive abciximab infusion at standard regimen prior undergoing percutaneous coronary intervention for STEMI followed by BMS implantation in the culprit lesion
  • Experimental: 2
    • Abciximab followed by implantation of sirolimus-eluting stent in the culprit lesion
  • Experimental: 3
    • tirofiban infusion followed by bare metal stent implantation
  • Experimental: 4
    • tirofiban and sirolimus-eluting stent

Clinical Trial Outcome Measures

Primary Measures

  • The evaluation of the degree of ST-segment resolution after the mechanical intervention.
    • Time Frame: 90 minutes after last balloon inflation
  • The cumulative rate of death for any cause, reinfarction and target vessel revascularisation
    • Time Frame: 8 months

Secondary Measures

  • Death, recurrent acute myocardial infarction, target vessel revascularization and target lesion revascularisation, considered separately or in combination.
    • Time Frame: at any time during follow-up
  • The evaluation of the cost-effectiveness of the involved experimental treatments.
    • Time Frame: 8 months, 1,3 and 5 years
  • stent thrombosis according to the ARC classification
    • Time Frame: any time during follow-up
  • the degree of cumulative or single lead ST segment resolution at time frames different from the primary endpoint. the degree of residual ST segment elevation.
    • Time Frame: immediately after intervention, at 90 minutes and at discharge
  • bleeding rate defined according to different classifications including TIMI, Acuity, GUSTO and Steeple.
    • Time Frame: at 30 days, 1 year, 3 and 5 years

Participating in This Clinical Trial

Inclusion Criteria

  • ST segment elevation myocardial infarction – Schedule for primary percutaneous coronary intervention – Informed consent Exclusion Criteria:

  • Administration of fibrinolytic or any GP IIb/IIIa inhibitors for the treatment of current acute myocardial infarction or within 1 month before it – History of bleeding diathesis or allergy to the studies drug – Major surgery within 30 days – Limited life expectancy, e.g. neoplasms, others – Pregnancy

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Marco Valgimigli
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Marco Valgimigli, Head of the Catheterization laboratory – Università degli Studi di Ferrara
  • Overall Official(s)
    • Roberto Ferrari, Professor, Study Chair, Cattedra di Cardiologia, Azienda Ospedaliera Universitaria di Ferrara, Italy

References

Valgimigli M, Percoco G, Malagutti P, Campo G, Ferrari F, Barbieri D, Cicchitelli G, McFadden EP, Merlini F, Ansani L, Guardigli G, Bettini A, Parrinello G, Boersma E, Ferrari R; STRATEGY Investigators. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA. 2005 May 4;293(17):2109-17. doi: 10.1001/jama.293.17.2109.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.